Cited 0 times in Scipus Cited Count

A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer

DC Field Value Language
dc.contributor.authorPark, SJ-
dc.contributor.authorChang, SJ-
dc.contributor.authorSuh, DH-
dc.contributor.authorKong, TW-
dc.contributor.authorSong, H-
dc.contributor.authorKim, TH-
dc.contributor.authorKim, JW-
dc.contributor.authorKim, HS-
dc.contributor.authorLee, SJ-
dc.description.abstractBACKGROUND: PHI-101 is an orally available, selective checkpoint kinase 2 (Chk2) inhibitor. PHI-101 has shown anti-tumour activity in ovarian cancer cell lines and impaired DNA repair pathways in preclinical experiments. Furthermore, the in vivo study suggests the synergistic effect of PHI-101 through combination with PARP inhibitors for ovarian cancer treatment. The primary objective of this study is to evaluate the safety and tolerability of PHI-101 in platinum-resistant recurrent ovarian cancer. METHODS: Chk2 inhibitor for Recurrent EpitheliAl periToneal, fallopIan, or oVarian cancEr (CREATIVE) trial is a prospective, multi-centre, phase IA dose-escalation study. Six cohorts of dose levels are planned, and six to 36 patients are expected to be enrolled in this trial. Major inclusion criteria include >/= 19 years with histologically confirmed epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal cancer. Also, patients who showed disease progression during platinum-based chemotherapy or disease progression within 24 weeks from completion of platinum-based chemotherapy will be included, and prior chemotherapy lines of more than five will be excluded. The primary endpoint of this study is to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of PHI-101. DISCUSSION: PHI-101 is the first orally available Chk2 inhibitor, expected to show effectiveness in treating recurrent ovarian cancer. Through this CREATIVE trial, DLT and MTD of this new targeted therapy can be confirmed to find the recommended dose for the phase II clinical trial. This study may contribute to developing a new combination regimen for the treatment of ovarian cancer. TRIAL REGISTRATION: Identifier: NCT04678102 .-
dc.subject.MESHAntineoplastic Agents, Immunological-
dc.subject.MESHCarcinoma, Ovarian Epithelial-
dc.subject.MESHCheckpoint Kinase 2-
dc.subject.MESHDose-Response Relationship, Drug-
dc.subject.MESHFallopian Tube Neoplasms-
dc.subject.MESHImmune Checkpoint Inhibitors-
dc.subject.MESHMaximum Tolerated Dose-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Recurrence, Local-
dc.subject.MESHOvarian Neoplasms-
dc.subject.MESHPeritoneal Neoplasms-
dc.subject.MESHProspective Studies-
dc.titleA phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer-
dc.subject.keywordChk2 inhibitor-
dc.subject.keywordovarian cancer-
dc.subject.keywordPARP inhibitor-
dc.subject.keywordPhase IA-
dc.contributor.affiliatedAuthorChang, SJ-
dc.contributor.affiliatedAuthorKong, TW-
dc.type.localJournal Papers-
dc.citation.titleBMC cancer-
dc.identifier.bibliographicCitationBMC cancer, 22(1). : 28-28, 2022-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Obstetrics & Gynecology
Files in This Item:


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.